Kate Yen, Auron Therapeutics founder and CEO
July 20, 2022 10:56 AM EDTUpdated 02:07 PM
Financing
Startups

Armed with a $48M Se­ries A, Au­ron is look­ing to ap­ply ma­chine learn­ing in can­cer treat­ment

Tyler Patchen

News Reporter

The hype of ma­chine learn­ing has man­aged to bag se­ri­ous cash from in­vestors over the past year, and the lat­est biotech to en­ter …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

A service from the Financial Times